GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (SHSE:688235) » Definitions » Operating Margin %

BeiGene (SHSE:688235) Operating Margin % : -60.50% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BeiGene Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. BeiGene's Operating Income for the three months ended in Dec. 2023 was ¥-2,740 Mil. BeiGene's Revenue for the three months ended in Dec. 2023 was ¥4,530 Mil. Therefore, BeiGene's Operating Margin % for the quarter that ended in Dec. 2023 was -60.50%.

Good Sign:

BeiGene Ltd operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for BeiGene's Operating Margin % or its related term are showing as below:

SHSE:688235' s Operating Margin % Range Over the Past 10 Years
Min: -10940.19   Med: -175.28   Max: -41.3
Current: -49.12


SHSE:688235's Operating Margin % is ranked better than
62.94% of 1028 companies
in the Biotechnology industry
Industry Median: -171.86 vs SHSE:688235: -49.12

BeiGene's 5-Year Average Operating Margin % Growth Rate was 31.20% per year.

BeiGene's Operating Income for the three months ended in Dec. 2023 was ¥-2,740 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was ¥-8,559 Mil.

Warning Sign:

BeiGene Ltd had lost money in 92% of the time over the past 12quarters.


BeiGene Operating Margin % Historical Data

The historical data trend for BeiGene's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Operating Margin % Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -224.16 -536.69 -122.31 -126.40 -49.12

BeiGene Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -123.29 -82.91 -53.54 -17.15 -60.50

Competitive Comparison of BeiGene's Operating Margin %

For the Biotechnology subindustry, BeiGene's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's Operating Margin % distribution charts can be found below:

* The bar in red indicates where BeiGene's Operating Margin % falls into.



BeiGene Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

BeiGene's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-8623.477 / 17556.174
=-49.12 %

BeiGene's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-2740.373 / 4529.807
=-60.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BeiGene  (SHSE:688235) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


BeiGene Operating Margin % Related Terms

Thank you for viewing the detailed overview of BeiGene's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene (SHSE:688235) Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (SHSE:688235) Headlines

No Headlines